ABL is Pleased to Announce the TherapyEdge ViroScore Suite Platform is Now Available in Brazil

LUXEMBOURG & SAO PAULO, Brazil--()--Advanced Biological Laboratories (ABL) and Centro de Genomas are pleased to announce an agency agreement whereby Centro de Genomas will provide to the private and public sectors throughout Brazil, the ABL TherapyEdge products in Portuguese language. Beginning immediately Centro de Genomas will be supporting TherapyEdge™, ViroScore Suite™ and other online services primarily in the field of HIV/AIDS and viral hepatitis.

Through the agreement, Centro de Genomas will provide the advanced technical support and customer care that ABL TherapyEdge customers have come to appreciate and value highly. Centro de Genomas will offer customers expanded training and support via workshops and in-office training.

ABL and Centro de Genomas will work closely to develop strategic partnerships in Brazil. The combined alliance will seek to find a national or a regional corporate Diagnostic distributor for ABL's products line.

In accordance with its full commitment to support research, which include free medical tools and exchange of knowledge for the benefit of humanity, ABL has proposed Centro de Genomas to be in contact with any researcher, university and non-profit institution in Brazil to offer them royalty free sublicense rights on ABL US patents (Barry et al 6.081.786, 6.188.988 and their foreign equivalents including the ones prosecuted in Brazil).

"We're extremely pleased about this new partnership. We believe Brazilian infectious diseases specialists and patients will see the benefits of an integrated IT solution such as TherapyEdge. We have now TherapyEdge customized for the Brazilian market which should ease its widespread use," said Dr Chalom Sayada, CEO of ABL.

"ABL is the ideal company to partner with us. The electronic medical records market and online services is growing rapidly and fulfills important needs for integrated disease management in complex diseases such as HIV and viral hepatitis. It is completing our offer for advanced healthcare technologies," said Mrs Cinthia Vilhena, CEO of Centro de Genomas.

"The TherapyEdge ViroScore platform will offer Brazilian clinicians, virologists and epidemiologists with a suite of comprehensive tools to support their clinical routine but also their research from therapeutics to genomics," said Dr Ricardo Sobhie Diaz, Medical Director of Centro de Genomas.

More information about ABL at www.ablsa.com and Centro de Genomas at www.centrodegenomas.com.br

Contacts

Advanced Biological Laboratories (ABL), S.A.
Phone: +352 2638 8921
Fax: +352 2638 8938
Email: chalom@ablsa.com
Attention: Chalom B. Sayada (CEO)
or
Centro de Genomas
Phone: +55 11 5079 9593
Fax: +55 11 5585 9242
Email: cvilhena@centrodegenomas.com.br
Attention: Dra Cintia Vilhena

Contacts

Advanced Biological Laboratories (ABL), S.A.
Phone: +352 2638 8921
Fax: +352 2638 8938
Email: chalom@ablsa.com
Attention: Chalom B. Sayada (CEO)
or
Centro de Genomas
Phone: +55 11 5079 9593
Fax: +55 11 5585 9242
Email: cvilhena@centrodegenomas.com.br
Attention: Dra Cintia Vilhena